MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Cortical atrophy in cognitively impaired Parkinson’s disease patients

M.M. Almuqbel, T.R. Melzer, D.J. Myall, M.R. MacAskill, L. Livingston, K. Wood, T.L. Pitcher, R.J. Keenan, J.C. Dalrymple-Alford, T.J. Andrson (Christchurch, New Zealand)

Meeting: 2016 International Congress

Abstract Number: 1212

Keywords: Magnetic resonance imaging(MRI)

Session Information

Date: Wednesday, June 22, 2016

Session Title: Parkinson's disease: Neuroimaging and neurophysiology

Session Time: 12:00pm-1:30pm

Location: Exhibit Hall located in Hall B, Level 2

Objective: To explore whether cognitive impairment in Parkinson’s disease (PD) patients is associated with cortical thinning.

Background: Parkinson’s disease (PD) affects 1% of those over 60. Beyond various motor symptoms, most patients develop cognitive impairment, and often dementia (PDD). Reliable imaging markers would facilitate the most appropriate and timely intervention aimed at slowing the progression to dementia. The development of neuroprotective and disease-modifying therapies in PD has been hampered by a lack of clinically useful markers.

Methods: One-hundred and seventeen PD patients (68 with normal cognition, PDN; 29 meeting criteria for mild cognitive impairment, PDMCI; and 20 with dementia, PDD) and 51 healthy controls completed a comprehensive neuropsychological battery. Three-dimensional T1-weighted (spoiled gradient echo acquisition, TE/TR=2.8/6.6 ms, TI=400 ms, voxel size=0.98×0.98×1.0 mm3) images were acquired on a 3T GE scanner. Freesurfer was used to quantify cortical thickness. We used a general linear model with age, sex and UPDRS-III as covariates to assess whether cognitive decline was associated with cortical changes in PD.

Results: Relative to controls, patients with PDN exhibited no significant cortical thinning. Patients with mild cognitive impairment showed bilateral cortical thinning in the temporal lobes, and PDD exhibited marked atrophy in both the frontal and parietal cortical regions (corrected p<0.05). Relative to patients with normal cognitive status (PDN), patients with dementia (PDD) experienced significant bilateral cortical thinning in parietal regions. PDD patients also showed left frontal and parietal thinning relative to patients with mild cognitive impairment.

Conclusions: Our findings suggest that cortical thickness measured by MRI may be a potential marker for cognitive decline in PD. Based on these findings, it would be pertinent to explore the role of cortical thickness as a predictive marker for conversion to dementia in PD.

To cite this abstract in AMA style:

M.M. Almuqbel, T.R. Melzer, D.J. Myall, M.R. MacAskill, L. Livingston, K. Wood, T.L. Pitcher, R.J. Keenan, J.C. Dalrymple-Alford, T.J. Andrson. Cortical atrophy in cognitively impaired Parkinson’s disease patients [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/cortical-atrophy-in-cognitively-impaired-parkinsons-disease-patients/. Accessed September 28, 2023.
  • Tweet
  • Email
  • Print

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/cortical-atrophy-in-cognitively-impaired-parkinsons-disease-patients/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Welcome to the MDS Abstracts Site
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Advanced Search
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Welcome to the MDS Abstracts Site
  • Advanced Search
  • #23972 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Patients with Essential Tremor Live Longer than their Relatives
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Insulin dependent diabetes and hand tremor
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley